

Resource Summary Report

Generated by [PRECISE-TBI](#) on Sep 8, 2026

[cBioPortal](#)

RRID:SCR_014555

Type: Tool

Proper Citation

cBioPortal (RRID:SCR_014555)

Resource Information

URL: <http://www.cbioportal.org/>

Proper Citation: cBioPortal (RRID:SCR_014555)

Description: A portal that provides visualization, analysis and download of large-scale cancer genomics data sets.

Synonyms: cBioPortal for Cancer Genomics

Resource Type: data or information resource, database, portal

Defining Citation: [PMID:23550210](#), [PMID:22588877](#)

Keywords: cancer, genomics, database, portal, data sets, FASEB list

Funding: NCI U24CA143840;
NCRR RR031228-02

Availability: Please cite, Software is available via GitHub, Open source

Resource Name: cBioPortal

Resource ID: SCR_014555

Alternate URLs: <https://github.com/cBioPortal/cbioportal/>
<https://github.com/cBioPortal/cbioportal/blob/master/docs/README.md>

License: GNU Affero General Public License version 3

Record Creation Time: 20220129T080321+0000

Record Last Update: 20260905T133049+0000

Ratings and Alerts

No rating or validation information has been found for cBioPortal.

No alerts have been found for cBioPortal.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 10348 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Kim M, et al. (2026) Bone Metastatic Progression of Prostate Cancer Is Regulated by TRIM28-LDHA-Mediated Metabolism. *Molecular cancer research : MCR*, 24(2), 93.

Mogi M, et al. (2026) Pan-cancer analysis of RNA expression signatures associated with cancer tissue architecture. *British journal of cancer*, 134(1), 141.

Lee H, et al. (2026) PLD1 and PLD2 promote an immunosuppressive tumor microenvironment via CCL19-dependent macrophage polarization and PD-L1 induction. *Experimental & molecular medicine*, 58(6), 1870.

Rodriguez-Castellanos VE, et al. (2026) Radiation-Triggered Payload Release Enhances Bispecific Antibody Efficacy. *Cancer research*, 86(2), 453.

Mariancini A, et al. (2026) IL1R2 Deficiency Unleashes Neutrophil-Mediated Antitumor Potential in Sarcoma. *Cancer immunology research*, 14(5), 751.

Xu X, et al. (2026) A Multistep Immune-Competent Genetically Engineered Mouse Model Reveals Phenotypic Plasticity in Uveal Melanoma. *Cancer research*, 86(15), 3666.

Kumari N, et al. (2026) Metabolic stress conditions dictate MAPKAPK2-dependent efficiency of MEK1/2 inhibition in colorectal carcinoma. *Proceedings of the National Academy of Sciences of the United States of America*, 123(7), e2505331123.

Posani SH, et al. (2026) Mineralocorticoid and glucocorticoid receptor cooperation drives advanced phenotypes in triple-negative breast cancer. *Endocrinology*, 167(6).

Kim JK, et al. (2026) Loss of ABCA3 disrupts lipid balance and leads to AMPK-dependent suppression of SREBP1 in glioblastoma stem cells. *Oncogene*, 45(15), 1357.

Flint MS, et al. (2026) Signaling Under Stress: Targeting the Glucocorticoid Receptor in Cancer. *Cancer research*, 86(15), 3636.

Jamroze A, et al. (2026) Single-cell imaging analysis, therapeutic modeling and a Phase Ib trial validate BCL-2 as a target across heterogeneous castration-resistant prostate cancer. *Signal transduction and targeted therapy*, 11(1).

Dovey Z, et al. (2026) Adipokine Metabolic Drivers, Gut Dysbiosis, and the Prostate Microbiome: Novel Pathway Enrichment Analysis of the Adiposity-Based Chronic Disease-Prostate Cancer Network. *Cancers*, 18(2).

Wang D, et al. (2026) PRMT5 is Frequently Upregulated and a Potential Therapeutic Target in MTAP-deficient Malignant Peripheral Nerve Sheath Tumors. *bioRxiv : the preprint server for biology*.

Monteagudo-García Ó, et al. (2026) ZC3H13 Loss Drives Cancer Metastatic Progression by Disrupting m6A RNA Methylation. *Cancer research*, 86(3), 622.

Sun L, et al. (2026) Genomic Profile and Clinicopathologic Analyses of Wild-Type Gastrointestinal Stromal Tumors. *Molecular cancer research : MCR*, 24(4), 232.

Liu CT, et al. (2026) Mutant Isocitrate Dehydrogenase 1 Sensitizes Intrahepatic Cholangiocarcinoma Cells to MDM2 Inhibitors. *Cancer research communications*, 6(3), 616.

Dwead AM, et al. (2026) The YAP1-NPM1 nuclear complex regulates MYC and reveals a targetable oncogenic node. *iScience*, 29(5), 115588.

Zhu W, et al. (2026) Metabolic reprogramming promotes AR-V7 splicing via SRSF2 lactylation in castration-resistant prostate cancer. *Acta biochimica et biophysica Sinica*, Vol.(1).

Hitti E, et al. (2026) Profound alterations of cancer transcriptomes by the RNase L inhibitor ABCE1 through the modulation of UU/UA-dinucleotide rich transcript abundance. *RNA biology*, 23(1), 1.

Al-Mathkour MM, et al. (2026) The YAP1 and EPHA3 receptor tyrosine kinase axis regulates cellular plasticity and treatment response. *Cellular signalling*, 141, 112368.